Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
welgenaleucel
- Development stage
- Unknown
- Lead developer
- UWELL Biopharma
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Welgenaleucel is an autologous CD19-directed chimeric antigen receptor T cell (CAR-T) therapy. It consists of a patient's own T lymphocytes genetically engineered to express a CAR targeting CD19, a protein broadly expressed on the surface of B cells. The therapy is designed to selectively eliminate malignant B cells in conditions such as B-cell non-Hodgkin lymphoma and lymphoid leukemia by redirecting the immune response specifically toward CD19-expressing cells. Mechanistically, it acts through CD19 inhibition, gene transfer (integration of the CAR transgene by lentiviral vector), and replacement of defective T lymphocytes. Developed by UWELL Biopharma, it is being investigated primarily for relapsed/refractory B-cell malignancies[1][3][5][7].
- Brand names
- welgenaleucel
- Other names
- welgenaleucelUWC19UWC-19UWC 19
02
Targets
Beyond the preview
Go deeper on welgenaleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on welgenaleucel.